SELLAS (SLS) is a publicly traded Healthcare sector company. As of October 28, 2026, SLS trades at $10.14 with a market cap of $2.29B and a P/E ratio of -44.69. SLS moved -14.34% today. Year to date, SLS is +179.77%; over the trailing twelve months it is +527.32%. Its 52-week range spans $0.95 to $15.88. Analyst consensus is buy with an average price target of $30.00. Rallies surfaces SLS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Sellas' Phase 3 AML trial reaches 80th death, triggering final analysis: Sellas Life Sciences' Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia reached its prespecified 80th death, triggering final analysis. Preliminary topline results for overall survival are expected this quarter.
| Metric | Value |
|---|---|
| Price | $10.14 |
| Market Cap | $2.29B |
| P/E Ratio | -44.69 |
| EPS | $-0.25 |
| Dividend Yield | 0.24% |
| 52-Week High | $15.88 |
| 52-Week Low | $0.95 |
| Volume | 10.28M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-26.86M |
| Gross Margin | 0.00% |
1 analysts cover SLS: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $30.00.